|Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials|
M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ...
Chest 152 (2), 271-281, 2017
|Dose–response relationship between physical activity and risk of heart failure: a meta-analysis|
A Pandey, S Garg, M Khunger, D Darden, C Ayers, DJ Kumbhani, ...
Circulation 132 (19), 1786-1794, 2015
|A content analysis of smartphone–based applications for hypertension management|
N Kumar, M Khunger, A Gupta, N Garg
Journal of the American Society of Hypertension 9 (2), 130-136, 2015
|Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis|
A Pandey, S Garg, M Khunger, S Garg, DJ Kumbhani, KM Chin, JD Berry
Circulation: Heart Failure 8 (6), 1032-1043, 2015
|Optimal management of hereditary hemorrhagic telangiectasia|
N Garg, M Khunger, A Gupta, N Kumar
Journal of Blood Medicine, 191-206, 2014
|Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis|
M Khunger, AV Hernandez, V Pasupuleti, S Rakshit, NA Pennell, ...
JCO Precision Oncology 1, 1-15, 2017
|Combination of peri-and intratumoral radiomic features on baseline CT scans predicts response to chemotherapy in lung adenocarcinoma|
M Khorrami, M Khunger, A Zagouras, P Patil, R Thawani, K Bera, P Rajiah, ...
Radiology: Artificial Intelligence 1 (2), 180012, 2019
|Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience|
A Khunger, M Khunger, V Velcheti
Therapeutic advances in respiratory disease 12, 1753466618767611, 2018
|Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients|
M Khunger, PD Patil, A Khunger, M Li, B Hu, S Rakshit, A Basu, N Pennell, ...
PloS one 13 (10), e0197743, 2018
|Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non–small-cell lung cancer: a systematic review and meta-analysis|
M Khunger, P Jain, S Rakshit, V Pasupuleti, AV Hernandez, J Stevenson, ...
Clinical lung cancer 19 (3), e335-e348, 2018
|Evaluation of CROSS technique with 100% TCA in the management of ice pick acne scars in darker skin types|
N Khunger, D Bhardwaj, M Khunger
Journal of Cosmetic Dermatology 10 (1), 51-57, 2011
|Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset|
A Garg, M Khunger, S Seicean, MK Chung, PJ Tchou
JACC: Clinical Electrophysiology 2 (4), 487-494, 2016
|Subcision for depressed facial scars made easy using a simple modification|
N Khunger, M Khunger
Dermatologic Surgery 37 (4), 514-517, 2011
|Infection in autoimmune bullous diseases: a retrospective comparative study|
JS Lehman, M Khunger, CM Lohse
The Journal of Dermatology 40 (8), 613-619, 2013
|FRMD4A/RET: A novel RET oncogenic fusion variant in non–small cell lung carcinoma|
V Velcheti, R Thawani, M Khunger, S Mukhopadhyay, DJ Chute, ...
Journal of Thoracic Oncology 12 (2), e15-e16, 2017
|Premature clinical trial discontinuation in the era of immune checkpoint inhibitors|
M Khunger, S Rakshit, AV Hernandez, V Pasupuleti, K Glass, MD Galsky, ...
The Oncologist 23 (12), 1494-1499, 2018
|A case of a patient with idiopathic pulmonary fibrosis with lung squamous cell carcinoma treated with nivolumab|
M Khunger, V Velcheti
Journal of Thoracic Oncology 12 (7), e96-e97, 2017
|Computer-extracted features relating to spatial arrangement of tumor infiltrating lymphocytes to predict response to nivolumab in non-small cell lung cancer (NSCLC).|
C Barrera, P Velu, K Bera, X Wang, P Prasanna, M Khunger, A Khunger, ...
Journal of Clinical Oncology 36 (15_suppl), 12115-12115, 2018
|Computer extracted features of cancer nuclei from H&E stained tissues of tumor predicts response to nivolumab in non-small cell lung cancer.|
X Wang, C Barrera, P Velu, K Bera, P Prasanna, M Khunger, A Khunger, ...
Journal of Clinical Oncology 36 (15_suppl), 12061-12061, 2018
|Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.|
PD Patil, M Khunger, S Rakshit, J Stevenson, NA Pennell, P Elson, ...
Journal of Clinical Oncology 35 (15_suppl), 11547-11547, 2017